by the remaining six SF-36 subscale scores. Prevalence of anxiety (18.1% vs. 19.3%, adjusted OR = 1.00 (0.74, 1.36); p = 1.00) and depression (7.2% vs. 9.8%, adjusted OR = 0.74 (0.48, 1.16); p = 1.00) were similar between melanoma survivors and controls. Conclusion Long-term early stage melanoma survivors report similar general QOL and mental health compared to population controls. Further research is needed to identify concerns more specific to melanoma.
Introduction
The incidence of cutaneous melanoma has been increasing in fair-skinned populations for the past 40 years [1] , with the World Health Organization estimating that 132,000 people worldwide will be diagnosed with melanoma in 2016 [2] . While melanoma is deadly at advanced stages, most people are diagnosed at an early stage and have a good prognosis [3] , however little is known about the specific long-term survivorship issues they face [4] .
Change in quality of life (QOL) is a recognized major health outcome of cancer diagnosis and treatment, which may impact a patient's prognosis, including survival [5, 6] . QOL differs by cancer diagnosis, stage of disease, and time from diagnosis [7, 8] . As most melanoma survivors are treated with surgery only, particularly those with early stage disease, it has been postulated that QOL issues in this population are likely psychological in nature [4] . Studies among melanoma survivors have found that approximately 30% have clinically significant levels of distress [9] , which is similar to other cancers [4] . Adjuvant therapy
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Most studies to date exploring QOL concerns among melanoma survivors did not have a control group with measured potential confounders, thereby limiting the conclusions that can be drawn from them. The objective of this study was to compare QOL and emotional health between long-term melanoma survivors and population controls. This allowed for the determination of which specific dimensions of QOL may be impaired in long-term melanoma survivors and whether additional psychological support is needed following diagnosis and treatment.
Methods
A cross-sectional survey of long-term melanoma survivors and population controls from a previously conducted case-control study was carried out in 2015; details for the original study are provided elsewhere [16] . Approval for this study was granted by the University of Minnesota Institutional Review Board and the Minnesota Cancer Surveillance System. We recruited participants from the Skin Health Study (SHS), a population-based case-control study conducted from 2004 to 2009 to assess indoor tanning use and risk of melanoma [17] . Individuals with invasive cutaneous melanoma diagnosed between July 2004 and December 2007, ages 25-59, and with a state driver's license or state identification card were identified by the Minnesota Cancer Surveillance System and eligible to participate. Controls were randomly selected from the Minnesota state driver's license and state identification card list and frequency-matched to cases in a 1:1 ratio on age (in 5-year age groups) and gender. A total of 1167 cases (84.6% among eligible) and 1101 controls (69.2% among eligible) participated in the original study.
All SHS participants who were alive at the time of the survey administration were identified for this cross-sectional survey. A total of 80 (6.9%) cases and 15 (1.4%) controls had died since the original SHS study was completed. Participants were recruited by mail to complete an online or paper survey using methods outlined by Dillman to maximize response [18] . QOL was measured in both melanoma survivors and controls using the Medical Outcomes Study Short Form 36 (SF-36) version 2 [19] . Mental health was measured using the Hospital Anxiety and Depression Survey (HADS), an instrument which includes 14 items [20] . The proportions of individuals with potentially clinically meaningful depression and anxiety were calculated using the established cut-off of 8 (out of 21) for each scale [21] .
Updated demographic and information on co-morbidities since their original participation in the SHS was obtained.
Means ± standard deviations (SD) and the size of the differences (effect size − Cohen's d; difference in means divided by the standard deviation) are presented for the SF-36 subscales. Effect sizes of 0.35-0.50 have been shown to be clinically relevant for the SF-36 subscales [22] . Comparisons of the SF-36 subscale scores between melanoma survivors and population controls were conducted using multivariate linear regression models. Both gender and age-adjusted and fully-adjusted models were conducted and the difference in least squares means and associated 95% confidence intervals (CI) are presented. Potential confounders, identified a priori, included age at survey, gender, education, income, marital status, body mass index, current smoking status and number of co-morbidities. The proportions of melanoma survivors and population controls with potentially clinically significant depression and/or anxiety based on the HADS were compared using multivariate logistic regression models; odds ratios (OR) and 95% CI are presented. Planned stratified analyses were conducted by age group (30-39, 40-49, 50-59, and 60-72 years) and gender. Due to the number of statistical tests performed, p values were adjusted to account for multiple comparisons using the Holm method [23] . Data were analyzed using SAS version 9.4 (Cary, NC). Adjusted p values <0.05 were considered statistically significant.
Results
The final response rate was 61.0%, with 724 (62.0%) melanoma survivors and 660 (59.9%) controls of those who originally participated in the Skin Health Study completing the survey. A total of 21 controls self-reported a melanoma diagnosis and were therefore excluded from analyses. Those who completed the survey were generally similar to those who did not respond, though they were older, more likely to have completed college, and less likely to have ever used indoor tanning. When examined separately by melanoma survivors and controls, these differences were similar. Melanoma survivors and population controls were not statistically significantly different across the demographic and health characteristics with the exceptions of race and smoking status (Table 1) .
Melanoma survivors were diagnosed an average of 9.6 ± 1.0 years prior to completing the survey; the majority (85.6%) had stage I disease and received surgery only. A minority had lymph node dissection (34.8%). Among the respondents, 27 (3.8%) reported a recurrence of their melanoma and 20 (2.8%) reported being diagnosed with metastatic disease since the original diagnosis.
Compared to population controls, melanoma survivors reported similar QOL measures across all SF-36 scales (Table 2 ). After adjustment for potential confounders, melanoma survivors had statistically significantly higher scores, but only modestly so, for physical functioning (90.5 ± 16.2 vs. 86.9 ± 18.5, p = 0.003) and bodily pain (76.9 ± 21.4 vs. 72.3 ± 21.7, p = 0.01). These differences, however, did not reach the criterion for clinical significance as no scales had effect sizes exceeding 0.35. No statistically or clinically significant differences in the mental health, vitality, roleemotion or social functioning subscales between melanoma survivors and controls were observed. Finally, no differences were observed in the proportion of melanoma survivors compared to controls with anxiety (18.1% vs. 19.3%, adjusted OR = 1.00 (0.74, 1.36); p = 1.00) or depression (7.2% vs. 9.8%, adjusted OR = 0.74 (0.48, 1.16); p = 1.00).
Few differences in QOL between melanoma survivors and controls were observed by age or gender. Only among persons ages 50-59 years did melanoma survivors report statistically and potentially clinically significantly better general health, physical functioning, bodily pain and physical role functioning QOL compared to population controls (effect sizes ranged from 0.27 to 0.36; data not shown). All other SF-36 subscales were similar between melanoma survivors and controls when stratified by age or gender. None of the differences observed for comparisons of rates of anxiety and depression between melanoma survivors and controls were statistically significant within the separate age or gender groups. A secondary analysis limiting the cases to those with Stage I disease, compared with controls, found similar results; there were too few cases with advanced stage disease to draw conclusions in this subset.
Discussion
Long-term melanoma survivors participating in this cross-sectional study reported similar QOL compared to population controls. This is the largest study of melanoma survivors to date to compare long-term QOL and mental health to similarly recruited controls and that allowed for adjustment of confounding factors.
Results from this investigation are consistent with the growing literature on the effects of cancer on QOL, signifying that survivors of cancers with generally good prognoses return to physical and emotional health levels similar to the general population over time [24] . It has been suggested that the act of surviving a cancer may even be associated with improved perception of QOL [25] , which may explain why some outcomes were higher in melanoma survivors compared to controls. In addition, the survivors who participated in this study had primarily early stage melanoma and therefore few received adjuvant therapy, which may also contribute to the lack of differences in QOL. Further, these survivors were almost 10 years post-diagnosis, meaning that any physical or emotional concerns at the time of diagnosis and treatment may have dissipated by the time of the survey.
Limitations of note included the collection of data at a single time point and lack of QOL data at the time of diagnosis, which may be the most salient survivorship phase for melanoma survivors. Though participants were generally similar to those who did not participate, survivors with poorer QOL may have died or not responded to the survey, thereby providing a more optimistic view of QOL for melanoma survivors compared to persons without melanoma.
Consistent with data for long-term survivors of other cancers [24] , our results suggest that long-term melanoma survivors may not have the need for an intervention focused on general QOL. Further investigation using disease-specific measures of QOL is needed to identify challenges related to a melanoma diagnosis that would not be pertinent to controls. Additional data are also needed to understand the QOL of advanced stage melanoma survivors, outside of a clinical trial. Overall, these data are encouraging for people diagnosed with melanoma, providers, and public health researchers alike, as the number of melanoma survivors will continue to rise over the next few decades.
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